Insulin and Diabetes Flashcards

1
Q

What is diabetes?

A

Diabetes is a chronic health condition that affects how your body turns food into energy.

Glucose not correctly transported in muscles and adipose tissue.​

Fat not correctly stored in adipose tissue.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How is insulin synthesised?

A

Synthesised in B-cells of the Islets of Langerhans in the pancreas.

Synthesised as a single polypeptide called pro-insulin ​

Hydrolysed at two points to form two chains, these are linked by disulphide bridges. ​

The “inactive” segment released by hydrolysis is termed the C-peptide​.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How is insulin secreted?

A

Glucose is major stimulus to insulin secretion.

It enters the B cells via a non-insulin dependant transporter and is metabolised​.

ATP is produced, this inactivates ATP-dependent hyperpolarising K+ channel​. This channel becomes blocked so K+ can’t leave the cell. K+ accumulate at the cell membrane.

This leads to depolarisation of the B-cells​.

Calcium-dependent channels release insulin​.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are some other stimuli of insulin secretion?

A

Parasympathetic vagal activity (cephalic phase of secretion of insulin, starts before meal ingestion-depends on muscarinic M3 receptors). ​

Gastrointestinal hormones (gastrointestinal phase of secretion, starts when food enters the stomach and duodenum)​.

Glucagon (secreted by the a pancreatic cells)​.

Some amino acids, particularly alanine, glycine, arginine, leucine​.

Glucagon-like peptides (GLP): potentiate glucose-induced insulin secretion (but do not stimulate insulin secretion by themselves). ​

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What inhibits insulin secretion?

A

Sympathetic innervations ​(a2-adrenoceptor-dependent process, involved in stress response)​. These receptors induce the hyperpolarisation of the insulin-secreting cells​.

Somatostatin (secreted by D pancreatic cells, paracrine modulation)​. Most of these receptors produce a rise in intracellular calcium leading to the release of insulin.​

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How does glucose move into muscle cells and adipose tissue?

A

The process of GLUT4 translocation involves the movement to the cell surface of vesicles containing the glucose transport protein, GLUT4, responsible for bringing sugar into the cell.

Insulin receptor substrates form complexes with docking proteins, and promote GlUT4 translocation.

Exercise stimulates glucose transport by pathways that are independent of IRS.​

Not all tissues are dependent on insulin for glucose entry (brain, liver, kidney…) when insulin receptor is no more activated, glucose transporter is internalised back in intracellular vesicles.​

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What does insulin do to glucose in the liver?

A

Insulin stimulates glycogen synthesis (glycogenesis).

Inhibits synthesis of new glucose (inhibits gluconeogenesis)​.

Stimulates glycolysis (for the synthesis of fatty acids).

Resulting effect: prevents glucose output from the liver​.

Suppresses lipolysis and favours synthesis of fatty acid and cholesterol. ​

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What does insulin do to glucose in the muscles?

A

Stimulates glucose uptake (translocation of GLUT-4).​

Stimulates amino acid uptake and protein synthesis​.

Glucose will be used for glycolysis and synthesis of muscle glycogen.​

Resulting effect: promotes ATP production and fuel storage​.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What does insulin do to glucose in adipose tissue?

A

Stimulates glucose uptake (translocation of GLUT-4), and is converted into glycerol-phosphate​.

Promotes triglyceride storage.​

Inhibits release of fatty acids and stimulates lipogenesis.​

Activates adipose tissue lipoprotein lipase​ (hydrolyse triglycerides in chilomicrons and VLDL)​.

​Stimulate fatty acid transport ​(translocation of FATP ​fatty acid transport protein)​.

​Resulting effect:​ promotes deposition ​of circulating fat.

In summary:

Insulin exerts its effect by inducing Lipoprotein lipase (LPL) so that circulating triglycerides are hydrolyzed and free ​fatty acids can enter the adipocyte (through the FATP –fatty​ acid transport protein- which is also insulin-induced). ​

Inside the adipocyte, they will reform triglycerides ​(re-esterification).​

Insulin is also required for the transport of glucose, which is ​needed for re-esterification of the triglycerides once inside the ​adipocyte (converted into glycerol phosphate). ​

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What effects does insulin have on protein metabolism?

A

Promotes amino acid uptake and protein synthesis in a number of tissues (muscle).​

Decreases protein catabolism in the liver.​

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is gluconeogenesis?

A

Synthesis of new glucose (induced by adrenaline and glucagon, cortisol).​

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is glycolysis?

A

Degradation of glucose into small products (induced by insulin) for ATP or fatty acid synthesis​.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is glycogenolysis?

A

Degradation of glycogen into glucose (glucagon, adrenaline)​.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is glycogenesis?

A

Synthesis of glycogen from glucose (insulin, cortisol).​

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is lipolysis?

A

Degradation of fatty acid (inhibited by insulin)​.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is lipogenesis?

A

Synthesis of fatty acid and triglyceride (insulin)​

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is somatostatin?

A

It is a pancreatic hormone that is synthesised by the D cells​.

5 different somatostatin receptors, all are inhibitory receptors (inhibit cAMP production and hyperpolarise target cells)​.

Act primarily in a paracrine manner (1/2 life 3 min) to inhibit the secretion of both insulin and glucagon.​

On the digestive system: ​

Decreases rate of nutrient absorption​.

Inhibits GI hormones secretion (will reduce exocrine pancreatic secretion).​

Suppresses gastric secretion.​

Lowers the rate of gastric emptying, and reduces intestine contraction. ​

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is glucagon?

A

It is a pancreatic hormone that counteracts what insulin is doing.

It is synthesized first as proglucagon and processed to glucagon within alpha cells of the pancreatic islets.

Important role in maintaining normal concentrations of glucose in blood by potently increasing blood glucose levels. ​

​Control over two pivotal metabolic pathways within the liver:​

Stimulates breakdown of glycogen into glucose​.

Stimulates gluconeogenesis​.

Secretion is activated by low levels of glucose, high levels of some amino acids and exercise​.

Secretion is inhibited by insulin and high levels of glucose.

19
Q

What are incretins?

A

Incretins are gastro-intestinal hormones which regulates insulin secretion.

Glucagon-like peptide - gastrointestinal hormone, derived from the transcription product of the proglucagon gene.

Secreted by ileal L cells in response to the presence of nutrients in the GI tract.​

​Strongly potentiates glucose-mediated insulin secretion, and pro-insulin synthesis, stimulates regeneration of beta cells​.

Potently inhibits glucagon secretion.​

​Rapidly degraded by peptidase, biological effect is limited by its very short half life (<2 min). High therapeutic value.​

20
Q

What is amylin?

A

It is co-secreted with insulin from the pancreatic beta cells in response to a rise in blood glucose. ​

Attenuates blood sugar fluctuation, and improves overall glycaemic control.​

In Type 2 diabetes, certain forms of amylin may aggregate into fibrils and may induce damages to the beta cell and ultimately may restrain release and peripheral actions of insulin. ​

In summary:

Reduces postprandial glucagon secretion.

Regulates gastric emptying of food into the small intestine. ​

May suppress intake of food by causing the central nervous system to signal satiety. ​

21
Q

What are pancreatic polypeptides?

A

Synthesized in the F-cells of the Islets of Langerhans.

Released into the plasma following the ingestion of food. ​

Inhibits the stimulation of gastric and pancreatic exocrine secretions. ​

22
Q

What is type 1 diabetes?

A

Insulin dependent diabetes mellitus (IDDM).

Onset is common in childhood.​

Causes: ​

Likely a viral infection that triggers an autoimmune disease which destroys islets.​

Genetic defect in the synthesis of insulin (rare)​.

Genetic predisposition: moderate​.

Insulin therapy is essential to prevent ketoacidosis.

23
Q

What is type 2 diabetes?

A

Non-insulin dependent diabetes mellitus.

More common than Type 1.

Less prone to ketoacidosis (if well controlled), but other metabolic complications can be very serious .​

Insulin is sometimes needed but not essential to survival.​

Genetic predisposition: high.

Subdivided into obese and non-obese.​

Causes:​

Reduction in insulin secretion.

Insulin resistance (may be lack of receptors).

24
Q

What are the symptoms of diabetes?

A

The 3 P’s:

Polyuria - constantly need to urinate.
Polydypsia - constantly thirsty.
Polyphagia - state of starvation.

Tissue damage:

Increased protein glycosylation.
Conversion of glucose to sorbitol by aldose reductase.

Abnormalities in protein metabolism - muscle wasting/asthenia​.

Abnormalities in lipid metabolism ​- hypertriglyceridaemia, eventually ketosis and acidosis.

Resulting effects:​

Vascular complications, accelerated atheroma, increased thickness in small blood vessels, increased capillary fragility which causes lack of blood supply to retina, kidneys, extremities and other tissue damages.​

25
Q

What are AGE products?

A

Glucose accumulation in cells that are not dependent on insulin for glucose uptake and in extracellular fluid.

Non enzymatic glycolysation - glucose attaches to proteins without enzymatic activation (haemoglobin, collagen.

​Glycosylation of various proteins leads to irreversible advanced glycosylation end products (AGE), accumulating overtime in tissues with long turnover time, can occur also on lipids, and nucleic acids. ​

26
Q

What are some possible consequences of increased AGEs?​

A

Abnormal protein crosslinking (resistant to proteolytic digestion)​.

Trapping of albumin and other serum proteins into collagen. ​

Basement membrane thickening.​

Complement activation (immune system reaction) and immune complex formation.

Tissue damage​.

Activation of RAGE (receptor for AGE, in fact like a receptor for cytokines)​.

27
Q

What happens when sorbitol accumulates?

A

It should be converted to fructose but this is a limiited state so it could accumulate instead.

Sorbitol accumulation induces disturbance in phospholipid metabolism, alteration in membrane activity, decrease in myoinositol content, abnormal phospholipid metabolism, decrease in Na+, K+ and ATPase activity​.

28
Q

What is diabetic ketoacidosis?

A

Mainly type 1 diabetes.

Complication due to metabolism alteration in muscles and in liver.​

Due to the activation of lipolysis caused by the absence of insulin.​

29
Q

What are the treatment options for type 1 diabetes?

A

Insulin dependant.

Absolute insulin requirements (vary considerably between patients, may increase during pregnancy or illness)​.

Different types of insulin available slow acting, rapid acting, ultra rapid acting, ultra slow acting, pump etc…​

30
Q

What are the treatment options for type 2 diabetes?

A

Non-insulin dependant.

Glucose levels in type 2 can often be controlled by diet with weight reduction and exercise (but problem of insulin resistance), bariatric (partial removal of stomach) surgery very efficient in obese T2 patients.​

Drugs to increase insulin secretion (sulphonylurea drugs meglitinides)​.

Drug to reduce insulin resistance, like biguanides or glitazones​.

Drugs to slow down carbohydrate digestion​.

Drug to prevent glucose reabsoprtion from kidneys​.

Patients with Type 2 may require insulin​.

Other drugs to reduce cardiovascular complication can be useful (statins)​.

31
Q

Which types of insulin are given for type 1 diabetes?

A

Type I patients usually take a combination of short-(before a meal) and long-lasting preparations (once or twice a day); sometimes both preparations can be mixed together.​

Consider insulin pump therapy (continuous insulin infusion) for some TID patients (not stabilised by multiple injections or when multiple injections are not appropriate).

Devices (usually filled with short-acting insulin) delivers a continuous basal insulin infusion and patients activates bolus doses at meal times.

Generally good glycaemic controls in motivated patients.​

32
Q

What are some adverse effects from giving insulin for type 1 diabetes?

A

Patients can develop severe hypoglycaemia (sometimes coma), insulin glargine (very long lasting insulin seems safer).​

Glucagon and i.v. glucose in emergency if coma. Every years many diabetic patients died from hypoglycaemic coma.​

33
Q

What drugs are given to treat type 2 diabetes?

A

Sulphonureas promote insulin secretion (insulin secretagogues).

​Biguanide reduces hepatic glucose production (metformin)​.

​Thiazolinediones (glitazones) increase peripheral glucose utilisation​.

​Meglitinides​ - new class of insulin secretagogues​.

​Agents acting on GLP pathways​:

Dipeptidase inhibitors (vildagliptin, sitagliptin), prolong GLP action​.

​Alphaglucosidase inhibitors: reduce GI absorption of glucose​.

34
Q

What factors should be considered for antidiabetic therapy​?

A

Some drugs can induce hypoglycaemia in fasting condition (disadavantage of insulin-slow preparation and sulphonylurea, advantage of glucosidase inhibitors and biguanides)​.

​Some drugs do not attenuate the post-prandial glucose peak (disadvantage ​of sulphonylurea and some insulin-slow preparations, advantage of glucosidase inhibitors or fast-acting insulin)​.

Combination of treatment is often appropriate​.

35
Q

What is the mechanism of action of sulphonureas?

A

Developed from sulphonamide antibiotics.

Effective only in type II patients, when B cells are present.

Stimulate insulin secretion, by inactivating the K+ ATP-sensitive channel (induce B-cell depolarisation and release of insulin, these channels have an extracellular binding site for sulphonureas).​

36
Q

What are some disadvantages of sulphonureas?

A

Increase appetite​.

Can increase weight gain (problem in obese patients)​.

​Can induce severe hypoglycaemia (problem in older patients)​.

​Limited effects on postprandial (after meal) glucose​.

​Possible (adverse effects on cardiovascular systems.
(blockade of ATP-sensitive K+ channel in heart and vascular tissue). ​

37
Q

What is the mechanism of action of meglitinides?

A

Binds to sulphonurea receptors on the β-cells but at a different site​ with a greater affinity​.

ATP-dependent K+ channels close​ resulting in insulin secretion.​

More rapid effects than sulphonureas with shorter half-life, better for postprandial glucose and less hypoglycaemic effects.​

Site of Action - pancreatic β-cells​.

Not given as first choice, more expensive than sulphonureas.

38
Q

What is the mechanism of action of thiazolinediones (glitazones)?

A

Target insulin resistance by enhancing the effect of insulin on adipose tissues and the liver, thus improving hyperglycaemia and decreasing lipids in blood.​

Binds to a nuclear receptor (PPARg) and alters gene transcription of a number of genes critical for glucose and fat metabolism. PPAR receptors are found in insulin target tissue such as adipose tissue, muscle and liver.​

In some aspects, it will mimic or enhance insulin action without affecting ß-cell insulin secretion.​

Beneficial effects on adipocytes (induce LPL) glucose uptake in muscle, hepatic glucose metabolism.​

However, troglitazone withdrawn from UK due to possible hepatic toxicity.​

39
Q

What are the advantages and disadvantages of thiazolinediones (glitazones)?

A

Advantages:

Not hypoglycaemic​.

Decrease lipid levels (good for cardiovascular system)​.

Disadvantages:​

Limited effects in monotherapy​.

Associated with an increase in CHD (possibly due to excessive water retention –oedema leading to cardiac failure) and weight gain.​

40
Q

Why are biguanides used to treat type 2 diabetes?

A

Targets insulin resistance.

First choice drug - metformin (because of beneficial cv effects), particularly if patient is overweight.

Potentiates insulin effects by increasing insulin receptor sensitivity (tyrosine kinase activity).​

Increase glucose uptake by skeletal muscle and glucose metabolism in liver, decrease glucose absorption rate from the GI tract​.

Probable effect on hepatic mitochondria (decrease respiration)​.

41
Q

What are some advantages of biguanides?

A

Not hypoglycaemic, had some anorexic effects.

Decrease lipid levels, provide cardioprotection.

Can be used in combination with another antidiabetic drugs.​

42
Q

What is given if metformin and sulfonureas don’t work to treat type 2 diabetes?

A

Drugs that act on GLP (glucagon-like peptides)​.

Dipeptidase inhibitors:

These prolong the life of gut hormone GLP by inhibiting its enzymatic degradation, stimulate insulin secretion (in fact glucose-induced insulin secretion), slow down nutrient absorption, reduce satiety, may also stimulate regeneration of bcells (maybe very good long-term effect). ​

Advantages:

Induce weight loss and have few side effects. ​
Generally given in polypharmacy.​
Possible but questionable tumour promoting effect.

​Exenatide, liraglutide​:

Mimics the action of GLP, more stable GLP analogue,​

Administered subcutanously before a meal, same therapeutic action as DPI, but possibly more side effects (GI disturbances, nausea, vomiting).

In combination therapy in type 2 only, when other oral treatment did not work.

An advantage is induced weight loss.​

43
Q

What is the role of alphaglucosidase inhibitors?

A

Delay digestion of carbohydrate by inhibiting carbohydrates digestive enzymes such as amylase.

In theory, should reduce post-prandial peak of glucose, could even be used as adjunct therapy in type 1.

However they give unpleasant GI effects.​

44
Q

What is the role of sodium-glucose cotransporter 2 (SGLT2)?

A

eg: Dapagliflozin.

Reversibly inhibits sodium-glucose cotransporter in the renal proximal convulated tubule to reduce glucose re-absorbtion and increase glucose excretion in urine.

Recently licensed for type 2 diabetes as mono therapy or in combination with insulin or other antidiabetics except pioglitazone.

To be used only in patients with acceptable renal function.

Major drawback is that there is a risk of renal infection.​